Continue on TOI App
Open App
OPEN APP

BioAge discontinues mid-stage trial of obesity drug

BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.

The drug developer decided to stop the trial after liver transaminitis, or high levels of certain liver enzymes, were observed in patients receiving the experimental drug, azelaprag.

Tirzepatide is the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound.

The mid-stage trial enrolled about 220 individuals with obesity aged 55 years and older.

Start a Conversation

Post comment
Continue Reading
Follow Us On Social Media
end of article
More Trending Stories
Visual Stories
More Visual Stories
UP NEXT
Do Not Sell Or Share My Personal Information